Live Breaking News & Updates on Cardea bio

Stay informed with the latest breaking news from Cardea bio on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Cardea bio and stay connected to the pulse of your community

January Therapeutics today announced the appointment of Dr. Paul Grint to the Board of Directors

January Therapeutics today announced the appointment of Dr. Paul Grint to the Board of Directors
Share Article
Dr. Paul Grint is bringing his experience as CMO, CEO (Private & Public Companies), Chairman of the Board, and Board Member to help January's Board
SAN DIEGO (PRWEB)
May 05, 2021
Dr. Grint has served as the Executive Chairman of the Board of Directors of Cardea Bio since April 2020. He also has served as a member of the Board of Directors and as a member of the compensation committee of Amplyx Pharmaceuticals, Inhibikase Therapeutics and Synedgen.
From 2017 to 2019, Dr. Grint served as Chief Executive Officer of AmpliPhi Biosciences and as a member of AmpliPhi Bioscience’s Board of Directors from 2015 to 2019, additionally from 2014 to 2017 Dr. Grint served as Chief Executive Officer of Regulus Therapeutics, Inc., both publicly traded clinical stage biopharmaceutical companies.

Ampliphi-biosciences , Cardea-bio , Sam-ellis , Bartholomew-hospital-college , Regulus-therapeutics-inc , Schering , Mary-hospital-college , Amplyx-pharmaceuticals , Pfizer , University-of-london , Royal-college-of-pathologists , Plough-corporation

Global Biosensors Market (2021 to 2026) - Increasing Use of Biosensors to Monitor Glucose Levels in Individuals with Diabetes is Driving Growth

Share this article
Share this article
ResearchAndMarkets.com's offering.
The biosensors market is valued at USD 25.5 billion in 2021 and is projected to reach USD 36.7 billion by 2026; it is expected to grow at a CAGR of 7.5% from 2021 to 2026.
Metal-based nanoparticles can be efficiently used to detect nucleic acid sequences by exploiting their optoelectronic properties. Recent advancements in the field of nanotechnology have led to the utilization of nanomaterials, such as metal nanoparticles, oxide nanoparticles, magnetic nanomaterials, carbon materials, quantum dots, and metallophthalocyanines, to improve the electrochemical signals of biocatalytic events that occur at electrode/electrolyte interface. Nanomaterials, such as carbon nanotubes and indium oxide nanowires, are widely used to manufacture nanotechnology-based biosensors or nanobiosensors. Nanobiosensors have revolutionized the future of disease diagnosis. They are gaining importance in areas such as catalysis, optics, biomedical sciences, mechanics, magnetic, and energy science.

United-states , Dublin , Ireland , France , French , America , Cardea-bio , Nanomechanical-biosensors , Laura-wood , Microcantilever-biosensors , Eastprint-incorporated , Dynamic-company

SNP-Chip: CRISPR-Based Transistor Detects Single Point Mutations

SNP-Chip: CRISPR-Based Transistor Detects Single Point Mutations
"SNP-Chip" enables amplification-free, electronic, detection of point mutations in DNA from patients with Sickle-Cell Disease and ALS
Long before the COVID-19 pandemic shined a spotlight on CRISPR-based diagnostics, Kiana Aran, PhD, was developing the CRISPR-Chip. It was, according to Aran, the first transistor that uses CRISPR to search the genome for potential mutations. In addition, the graphene field-effect transistor (gFET) did not require amplification or sequencing of the nucleic acid.
Now, two years after its introduction, a group headed by Aran, co-founder and CSO at Cardea Bio, and assistant professor at the Keck Graduate Institute of Applied Life Sciences, is introducing an improved CRISPR-based gFET system, named SNP-Chip.

Keck-graduate-institute , California , United-states , San-diego , Lithuania , Lithuanian , Emmanuelle-charpentier , Michael-heltzen , Cardea-bio , Kary-mullis , Kiana-aran , Jennifer-doudna

CRISPR-Chip advance streamlines genetic testing for medical diagnostics and research

CRISPR-Chip advance streamlines genetic testing for medical diagnostics and research
indiaeducationdiary.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiaeducationdiary.in Daily Mail and Mail on Sunday newspapers.

Berkeley , California , United-states , Keck-graduate-institute , Lithuania , Vilnius , Vilniaus-apskritis , Irvine , Irina-conboy , Cardea-bio , Kiana-aran , Vilnius-university

CRISPR-SNP-chip enables amplification-free electronic detection of single point mutations

Loading video...
VIDEO: Keck Graduate Institute (KGI) Assistant Professor and University of California, Berkeley Visiting Scientist Dr. Kiana Aran first introduced the CRISPR-Chip technology in 2019. Now just two years later, she has...
view more
Credit: Keck Graduate Institute (KGI) and Cardea Bio
CLAREMONT, CA - Keck Graduate Institute (KGI) Assistant Professor and University of California, Berkeley Visiting Scientist Dr. Kiana Aran first introduced the CRISPR-Chip technology in 2019. Now just two years later, she has expanded on its application to develop CRISPR-SNP-Chip, which enables detection of single point mutations without amplification in Sickle Cell Disease and Amyotrophic lateral sclerosis (ALS).
"The field of CRISPR-based diagnostics is rapidly evolving due to CRISPR programmability and ease of use," Aran says. "However, the majority of CRISPR-based diagnostics platforms are still relying on target amplifications or optical detections. The reprogrammability of CRISPR combined with optics-free highly scalable graphene transistors will allow us to bring the diagnostics power of the CRISPR to its full potential.

Keck-graduate-institute , California , United-states , Lithuania , Vilnius , Vilniaus-apskritis , Irvine , Claremont , Jonathan-parkinson , Philip-collins , Francie-barron , Reza-hajian

CRISPR-SNP-Chip: Electronic Measurements of Single Nucleotide Polymorphisms Without DNA Amplification

CRISPR-SNP-Chip: Electronic Measurements of Single Nucleotide Polymorphisms Without DNA Amplification
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

University-of-california-irvine , California , United-states , Keck-graduate-institute , Lithuania , Vilnius , Vilniaus-apskritis , Rob-lozuk , Irina-conboy , Cardea-bio , Virginjus-siksnys , Kiana-aran

Lux Research Names the Top Digital Transformation Startups of 2020

Lux Research Names the Top Digital Transformation Startups of 2020
A new list highlights the most innovative digital transformation startups across four key trends
News provided by
Share this article
BOSTON, March 11, 2021 /PRNewswire/ --
Digital transformation means many things to many people, so it's important to segment and analyze startups developing foundational enabling technologies as well as key impacted applications, such as Industry 4.0 and digital health.
Lux Research's digital transformation experts are continuously monitoring industry megatrends and events to identify innovative startups in the space. Lux's new market map, "The Top Digital Transformation Startups of 2020," identifies 20 startups that were awarded a "Lux Positive" or "Lux Strong Positive" rating based on evaluations of their technology, business strategy, market positioning, and leadership.

Boston , Massachusetts , United-states , Jessica-bonner , Cardea-bio , Xandar-kardian , Illusive-networks , Lux-research , Research-at-lux , Top-digital-transformation-startups , Kevin-see , Vice-president

Army scientists team with DARPA to build COVID-19 air detector

Army scientists team with DARPA to build COVID-19 air detector
airforcetimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from airforcetimes.com Daily Mail and Mail on Sunday newspapers.

University-of-georgia , Georgia , United-states , Cardea-bio , Jared-adams , Matthew-coppock , Army-research-laboratory , Department-of-defense , Us-army-combat-capabilities-development , Jim-heath-laboratory , California-institute-of-technology , Defense-advanced-research-projects-agency

Cardea Bio Takes In $6.5M More In Series A

socaltech.com
San Diego-based
Cardea Bio, a startup that is developing molecular biology equipment which uses semiconductors to analyze samples, said on Tuesday that it has raised $6.5M more in its Series A funding. The company said the new funding was led by 3E Bioventures Capital, and also included existing investors. The company has now raised $20M in its Series
The story you have requested is only available to paid members of the socalTECH.com web site. Premium articles are restricted to paid members only. Please
login in order to access this members-only content, or

Cardea-bio , More-in-series , Diego-based-cardea-bio , Bioventures-capital , Semiconductor , Biology , Molecular , Capital , Venture , Bio , Cardea

Global CRISPR Technology Market Report 2020: COVID-19 Growth and Change - Market is Expected to Recover to Reach $1.55 Billion in 2023

Share this article
Share this article
ResearchAndMarkets.com's offering.
CRISPR Technology Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global crispr technology market.
Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery Plc., Integrated DNA Technologies, Inc. (Danaher), Origene Technologies, Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc., and GeneCopoeia, Inc.
The global CRISPR technology market is expected to increase from $0.76 billion in 2019 to $0.92 billion in 2020 at a compound annual growth rate (CAGR) of 20.91%. The exponential growth is mainly due to the COVID-19 outbreak that has led to the research for drugs for COVID-19 with gene-editing using CRISPR technology. The market is expected to reach $1.55 billion in 2023 at a CAGR of 19.13%.

Australia , United-states , India , Dublin , Ireland , America , Australian , Biophramaceuticals-hera-biolabs , Hera-biolabs , Cardea-bio , Laura-wood , Origene-technologies-inc